BioAtla (NASDAQ: BCAB) CMO receives 240,000-share time-based RSU award

Rhea-AI Filing Summary

Sievers Eric reported acquisition or exercise transactions in this Form 4 filing.

BioAtla, Inc. reported that Chief Medical Officer Eric Sievers received a grant of 240,000 shares of Common Stock in the form of time-based restricted stock units (RSUs) at no purchase price.

The RSU vests as to 25% of the shares on March 10, 2027, then 6.25% on the last day of each May, August, November, and February, subject to his continued service through each vesting date. Following this award, Sievers directly holds 598,705 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sievers Eric

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	240,000	$0.00	--

Holdings After Transaction: Common Stock — 598,705 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sievers Eric

(Last) (First) (Middle)

C/O BIOATLA, INC. 11085 TORREYANA ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAtla, Inc. [ BCAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		240,000(1)	A	$0	598,705	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 25% of the total number of shares on March 10, 2027, and thereafter, 6.25% of the total number of shares subject to the RSU shall vest on the last day of each May, August, November and February, subject to the reporting person's continued service through the applicable vesting date.

	Christian Vasquez, as Attorney-in-Fact for Eric Sievers	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioAtla (BCAB) Chief Medical Officer Eric Sievers report on this Form 4?

Eric Sievers reported receiving a grant of 240,000 shares of BioAtla Common Stock in the form of time-based RSUs. The award was recorded at a $0.00 per-share price and increased his direct holdings to 598,705 shares after the transaction.

How many BioAtla (BCAB) shares does Eric Sievers hold after the RSU grant?

After the reported RSU grant, Eric Sievers directly holds 598,705 shares of BioAtla Common Stock. This total includes the 240,000-share restricted stock unit award disclosed in the filing, which is structured to vest over time based on his continued service.

What is the vesting schedule for Eric Sievers’ 240,000 BioAtla (BCAB) RSUs?

The 240,000-share RSU vests 25% on March 10, 2027. Thereafter, 6.25% of the total shares vest on the last day of each May, August, November, and February, conditioned on Sievers’ continued service through each scheduled vesting date.

Is Eric Sievers’ BioAtla (BCAB) RSU award an open-market purchase or a grant?

The transaction is a grant/award acquisition, not an open-market purchase. It is coded as a Form 4 transaction type “A,” representing a restricted stock unit award at a $0.00 per-share transaction price, subject to the specified vesting schedule.

What type of security did Eric Sievers receive in the latest BioAtla (BCAB) Form 4?

Eric Sievers received Common Stock in the form of a time-based restricted stock unit (RSU) award covering 240,000 shares. The RSU structure means the shares vest over time as long as he continues to provide service through each vesting date.